To this end, multiple works have conducted disproportionality analyses of this association using the FAERS database and other retrospective analyses [19-22] which confirm clinical reportings of an increased risk of pancreatitis with GLP-1 agonist use. This evidence concerns the gene GLP1R and pancreatitis.